MindWalk CEO to join Jones AI Day panel on future of AI drug discovery

MindWalk Holdings Corp. President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones alongside Absci and a leading AI compute provider on June 15, 2026. The panel, "Partnering to Power the New Era of Drug Discovery," is part of Jones AI Day and will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle barriers in drug discovery, such as prolonged screening timelines and historically undruggable targets.

MindWalk's Technology Approach

MindWalk is a biology company that built AI on top of 25 years of wet-lab expertise. Its HYFT® technology powers ReefIQ™, the biological context layer for life sciences, which enriches biological data at ingestion and connects it across a continuously evolving knowledge representation of 660 million biological patterns and 25 billion relationships. The LensAI™ platform serves as the reasoning and application layer on top of this infrastructure. The architecture is designed to keep AI models and autonomous agents from hallucinating in high-consequence drug discovery workflows by grounding predictions in evolutionary constraint rather than statistical correlation.

Panel Discussion Focus

Dr. Bath is expected to discuss why the durable asset in biological AI is the enriched context layer rather than any individual model, and how that layer makes agentic AI trustworthy enough to deploy in regulated workflows. LensAI™ is currently in contracted, recurring arrangements with life-sciences customers. The panel will be moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail.

Event and Participant Details

The event is scheduled for Monday, June 15, 2026, at 12:00 p.m. ET and is hosted as part of Jones AI Day, which runs from 10:30 a.m. to 2:30 p.m. ET. Registration is open to institutional investors through Jones. The panelists include Dr. Jennifer Bath of MindWalk, Sean McClain, Founder and CEO of Absci, and senior healthcare and life-science strategy leadership from the AI compute provider.

Entity	Participant	Role
MindWalk Holdings Corp.	Dr. Jennifer Bath	Chief Executive Officer and President
Absci	Sean McClain	Founder and Chief Executive Officer
Leading AI compute provider	Senior leadership	Healthcare and life-science strategy

MindWalk Holdings Corp. has launched ReefIQ, a biological context layer designed to integrate fragmented discovery data for AI-enabled drug discovery and biologics development. The platform addresses the disconnect between connected biology and fragmented drug-discovery data by linking representations before AI workflows act on them. By transforming sequences, structures, assay outputs, omics, literature, and program history into a governed, queryable context, ReefIQ aims to preserve insights from all programs, including those that fail, to support trustworthy reasoning in regulated settings.

Technology Architecture

ReefIQ operates as a client biological context layer built on MindWalk's core HYFT biological pattern technology. HYFT provides the underlying biological representation foundation with explicit relationships across sequence, structure, function, mechanism, pathway, evidence, and literature. The system is supported by a Knowledge Graph comprising 660 million biological patterns and 25 billion relationships, refined over 20 years of curation.

Component	Function
HYFT	Provides the biological representation foundation.
ReefIQ	Organizes and governs the client biological context layer.
LensAI	Applies reasoning workflows to the connected context.

Strategic Importance

Dr. Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp., emphasized that the durable advantage in life-sciences AI lies in the biological context available for reasoning. "Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost," said Bath. "ReefIQ is designed to close it, preserving what every program learns as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy."

Operational Workflow

The platform allows LensAI and customer-selected agent models to retrieve, analyze, and generate hypotheses from connected biological context rather than isolated files. Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk, stated that the goal is to support retrieval, analysis, and hypothesis generation over connected biological context while preserving provenance, deployment flexibility, and customer-defined controls. LensAI is currently in contracted, recurring arrangements with life-sciences customers.